Innoviva, Inc.
NASDAQInnoviva heads into tonight's earnings release having shed nearly 8% over the past month, with shorts quietly accumulating and the broader peer group offering little support. Short interest has become the most telling feature of this setup. Bears have been adding steadily — SI has risen 7.2% over the past month to reach 9.5% of the free float, a meaningful level for a pharma…
Snapshot as of 25 Aug 2026
Innoviva heads into tonight's earnings release having shed nearly 8% over the past month, with shorts quietly accumulating and the broader peer group offering little support. Short interest has become the most telling…
Innoviva, Inc. heads into its Q1 2026 print tonight with options positioning nudging more defensive against a stock that has drifted quietly lower. The most notable pre-earnings signal is in options. Put/call activity…
Innoviva reported Q1 2026 results after the close on May 6, posting a massive EPS beat — $2.22 actual against a $0.36 consensus estimate — while revenue of $97.99 million came in slightly short of the $101.56 million…
Short interest updated daily, real-time options flow, analyst consensus deltas, 13F positioning, ORTEX Alpha signals, and every article ORTEX publishes for INVA — free to start on ORTEX.
Sign up for free →Open INVA on ORTEX